C4 Therapeutics, Inc. · NASDAQ:CCCC
Soleus Capital Master Fund, L.P. reported a 9.99% stake in C4 Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 12, 2026
Soleus Capital Master Fund, L.P. reported a 9.99% stake in C4 Therapeutics, Inc., 10,361,860 shares, as a passive investor on Dec 31, 2025. Filed Feb 12, 2026 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 10,361,860
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 9 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Soleus Private Equity Fund III, L.P. | 5.90% | 6,072,822 |
| Soleus Private Equity GP III, LLC | 5.90% | 6,072,822 |
| Soleus PE GP III, LLC | 5.90% | 6,072,822 |
| Soleus Capital Master Fund, L.P. | 9.99% | 10,361,860 |
| Soleus Capital, LLC | 9.99% | 10,361,860 |
| Soleus Capital Group, LLC | 9.99% | 10,361,860 |
| Soleus Capital Management, L.P. | 9.99% | 10,334,114 |
| Soleus GP, LLC | 9.99% | 10,334,114 |
| Guy Levy | 9.99% | 10,334,114 |
Source
Related
- C4 Therapeutics, Inc.
- Soleus Capital Master Fund, L.P.
- C4 Therapeutics, Inc. shareholders
- Form 4 · Anderson Kenneth Carl · Oct 2, 2026
- Form 4 · Grogan Donna Roy · Oct 2, 2026
- Form 4 · Adams Kendra · Sep 21, 2026
- Schedule 13G/A · Lynx1 Capital Management LP · Aug 14, 2026
- Schedule 13G/A · Squadron Capital Management LLC · Aug 14, 2026